Cohance Lifesciences Limited (BOM:543064)
433.25
+9.65 (2.28%)
At close: Sep 16, 2026
Cohance Lifesciences Revenue
Cohance Lifesciences had revenue of 4.22B INR in the quarter ending June 30, 2026, a decrease of -23.13%. This brings the company's revenue in the last twelve months to 21.42B, up 70.12% year-over-year. In the fiscal year ending March 31, 2026, Cohance Lifesciences had annual revenue of 22.69B, down -13.03%.
Revenue (ttm)
21.42B
Revenue Growth
+70.12%
P/S Ratio
7.57
Revenue / Employee
17.67M
Employees
1,212
Market Cap
162.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.69B | -3.40B | -13.03% |
| Mar 31, 2025 | 26.09B | 15.57B | 148.11% |
| Mar 31, 2024 | 10.51B | -2.89B | -21.56% |
| Mar 31, 2023 | 13.40B | 201.07M | 1.52% |
| Mar 31, 2022 | 13.20B | 3.11B | 30.75% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 86.08B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 35.75B |
| AstraZeneca Pharma India | 24.32B |
| Caplin Point Laboratories | 22.87B |
| FDC Limited | 21.90B |
| Morepen Laboratories | 19.51B |
Cohance Lifesciences News
- 6 weeks ago - Cohance Lifesciences Transcript: Q1 26/27 - Transcripts
- 6 weeks ago - Cohance Lifesciences Quarterly report: Q1 2027 - Filings
- 6 weeks ago - Cohance Lifesciences Slides: Q1 2027 - Filings
- 4 months ago - Cohance Lifesciences Transcript: Q4 25/26 - Transcripts
- 4 months ago - Cohance Lifesciences Quarterly report: Q4 2026 - Filings
- 4 months ago - Cohance Lifesciences Slides: Q4 2026 - Filings
- 4 months ago - Cohance Lifesciences Annual report: Q4 2026 - Filings
- 7 months ago - Cohance Lifesciences Transcript: Q3 25/26 - Transcripts